European Patent Convention

NeoDynamics will be granted another European patent for its pulse biopsy tools

Countries, Law, Foreign relations, European Patent Organisation, Biopsy, Interventional radiology, European Patent Convention, European Patent Bulletin, Breast cancer
Thursday, January 14, 2021 - 7:41am

STOCKHOLM, Jan. 14, 2021 /PRNewswire/ -- NeoDynamics AB (Spotlight Stock Market: NEOD), a MedTech company dedicated to advancing diagnosis and care of breast cancer, today announces that the European Patent Office (EPO) has issued a Communication under Rule 71(3) EPC (Notice of Allowance) and intends to grant a European patent for NeoDynamics pulse biopsy tools, including a multi-purpose driver supporting several different needle options.

Key Points: 
  • STOCKHOLM, Jan. 14, 2021 /PRNewswire/ -- NeoDynamics AB (Spotlight Stock Market: NEOD), a MedTech company dedicated to advancing diagnosis and care of breast cancer, today announces that the European Patent Office (EPO) has issued a Communication under Rule 71(3) EPC (Notice of Allowance) and intends to grant a European patent for NeoDynamics pulse biopsy tools, including a multi-purpose driver supporting several different needle options.
  • The decision will be published in the European Patent Bulletin, once the requirements concerning the translation of the claims and payment of all fees are fulfilled by NeoDynamics.
  • "This is very exciting and supports our launch of the pulse biopsy system NeoNavia, including three needle options for all ultrasound led biopsy procedures.
  • Ultrasound guided biopsy in breast and axilla is perceived as critical to ensure an early and adequate diagnosis and ultimately improve patient outcomes".

NeoDynamics will be granted another European patent for its pulse biopsy tools

Countries, Law, Foreign relations, European Patent Organisation, Biopsy, Interventional radiology, European Patent Convention, European Patent Bulletin, Breast cancer
Thursday, January 14, 2021 - 7:40am

STOCKHOLM, Jan. 14, 2021 /PRNewswire/ -- NeoDynamics AB (Spotlight Stock Market: NEOD), a MedTech company dedicated to advancing diagnosis and care of breast cancer, today announces that the European Patent Office (EPO) has issued a Communication under Rule 71(3) EPC (Notice of Allowance) and intends to grant a European patent for NeoDynamics pulse biopsy tools, including a multi-purpose driver supporting several different needle options.

Key Points: 
  • STOCKHOLM, Jan. 14, 2021 /PRNewswire/ -- NeoDynamics AB (Spotlight Stock Market: NEOD), a MedTech company dedicated to advancing diagnosis and care of breast cancer, today announces that the European Patent Office (EPO) has issued a Communication under Rule 71(3) EPC (Notice of Allowance) and intends to grant a European patent for NeoDynamics pulse biopsy tools, including a multi-purpose driver supporting several different needle options.
  • The decision will be published in the European Patent Bulletin, once the requirements concerning the translation of the claims and payment of all fees are fulfilled by NeoDynamics.
  • "This is very exciting and supports our launch of the pulse biopsy system NeoNavia, including three needle options for all ultrasound led biopsy procedures.
  • Ultrasound guided biopsy in breast and axilla is perceived as critical to ensure an early and adequate diagnosis and ultimately improve patient outcomes".

OncoZenge announces issue of European Patent related to BupiZenge®

Countries, Law, Government, European Patent Organisation, Mucositis, European Patent Office, European Patent Convention
Thursday, January 7, 2021 - 7:08am

STOCKHOLM, Jan. 7, 2021 /PRNewswire/ -- OncoZenge AB (publ), Moberg Pharma's subsidiary, today announced that the European Patent Office (EPO) has granted patent 3 284 459 which protects BupiZenge, currently in development for treatment of pain due to oral mucositis.

Key Points: 
  • STOCKHOLM, Jan. 7, 2021 /PRNewswire/ -- OncoZenge AB (publ), Moberg Pharma's subsidiary, today announced that the European Patent Office (EPO) has granted patent 3 284 459 which protects BupiZenge, currently in development for treatment of pain due to oral mucositis.
  • The new patent protects sustained-release lozenge containing bupivacaine, for treatment or alleviation of pain in the oral cavity.
  • It is a divisional of the previously granted European patent 2 701 681, that specifically protects the use of lozenges for treatment of pain due to oral mucositis for cancer patients.
  • "The patent significantly strengthens the intellectual property for BupiZengein Europe", Pirkko Tamsen, CEO of OncoZenge comments.

U.S. is the World Leader in Patenting Fourth Industrial Revolution (4IR) Technologies

Countries, Government, Law, European Patent Organisation, Patent, European Patent Office, Cision, InterPlanetary File System, European Patent Convention
Thursday, December 10, 2020 - 1:00pm

MUNICH, Dec. 10, 2020 /PRNewswire-PRWeb/ --A study published today by the European Patent Office (EPO) shows that innovation in fourth industrial revolution (4IR) technologies has accelerated significantly worldwide.

Key Points: 
  • MUNICH, Dec. 10, 2020 /PRNewswire-PRWeb/ --A study published today by the European Patent Office (EPO) shows that innovation in fourth industrial revolution (4IR) technologies has accelerated significantly worldwide.
  • The study, entitled "Patents and the Fourth Industrial Revolution the global technology trends enabling the data-driven economy", looks at all international patent families (IPFs) related to 4IR worldwide between 2000 and 2018.
  • The study finds that nearly 40,000 new IPFs were filed for these technologies in 2018 alone.
  • This means they accounted for more than 10% of all patenting activity worldwide that year.

Calidi Biotherapeutics Announces European Patent Granted by EPO: Combination Immunotherapy Approach for Treatment of Cancer

General Health, Pharmaceutical, Health, Oncology, Countries, Law, Foreign relations, European Patent Organisation, Virotherapy, Oncolytic virus, Immunotherapy, European Patent Office, European Patent Convention
Tuesday, December 1, 2020 - 2:00pm

Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, announced today that it has been granted a new patent from the European Patent Office (EPO).

Key Points: 
  • Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, announced today that it has been granted a new patent from the European Patent Office (EPO).
  • European Patent Number 3209382, Combination Immunotherapy Approach for Treatment of Cancer, secures Calidis proprietary technology platform, Supernova 1 (SNV1), composed of the oncolytic agent, CAL1 vaccinia virus, loaded into allogeneic, adipose-derived mesenchymal stem cells (AD-MSC).
  • Were very excited to be granted this European Patent to protect our innovative immunotherapy product and combination approach abroad, said Allan J. Camaisa, CEO and Chairman of Calidi Biotherapeutics.
  • As of the EP Grant Date, November 25, 2020, the European Patent covers Calidis combination immunotherapy approach and SNV1 product in 37 contracting European countries.

Cyxone files patent application to extend exclusivity of Rabeximod

Intellectual property law, Countries, Law, European Patent Organisation, Patent law, European patent law, Business law, European Patent Convention, European Patent Office, Patent application, Patent portfolio, Patent office
Tuesday, November 10, 2020 - 3:45pm

announced today that the company has filed for an extended patent protection of Rabeximod with the European Patent Office (EPO), that will be extended to other territories in due course.

Key Points: 
  • announced today that the company has filed for an extended patent protection of Rabeximod with the European Patent Office (EPO), that will be extended to other territories in due course.
  • An approval of the application will strengthen the company's intellectual property portfolio and generate a longer market exclusivity for Rabeximod.
  • Assuming a positive outcome, Rabeximod will enjoy a period of patent protection, effectively, until 2041.
  • The full details of the today's application will be made public in April 2022, 18 months following the application date.

Cyxone files patent application to extend exclusivity of Rabeximod

Intellectual property law, Countries, Law, European Patent Organisation, Patent law, European patent law, Business law, European Patent Convention, European Patent Office, Patent application, Patent portfolio, Patent office
Tuesday, November 10, 2020 - 3:43pm

announced today that the company has filed for an extended patent protection of Rabeximod with the European Patent Office (EPO), that will be extended to other territories in due course.

Key Points: 
  • announced today that the company has filed for an extended patent protection of Rabeximod with the European Patent Office (EPO), that will be extended to other territories in due course.
  • An approval of the application will strengthen the company's intellectual property portfolio and generate a longer market exclusivity for Rabeximod.
  • Assuming a positive outcome, Rabeximod will enjoy a period of patent protection, effectively, until 2041.
  • The full details of the today's application will be made public in April 2022, 18 months following the application date.

Immutep Announces Australian Patent Grant For IMP701 Antibody

Countries, Foreign relations, Law, Immutep, LAG3, European Patent Convention
Monday, November 9, 2020 - 1:00pm

Sydney, Australia, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company) announces the grant of patent no.

Key Points: 
  • Sydney, Australia, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company) announces the grant of patent no.
  • 2015229103 entitled Antibody molecules to LAG-3 and uses thereof by the Australian Patent Office.
  • This new Australian patent builds on the corresponding US patents announced in March 2018 and July 2020, a European patent announced in November 2019, and a Japanese patent announced in September 2019.
  • IMP701 is a therapeutic antibody originally developed by Immutep S.A. (now Immutep S.A.S.)

European Patent Office rules in favor of Sanofi and Regeneron concerning Praluent® (alirocumab)

Countries, Law, Government, European Patent Organisation, PCSK9, Alirocumab, Sanofi, Proprotein convertase, Regeneron Pharmaceuticals, European Patent Office, European Patent Convention, Evolocumab
Thursday, October 29, 2020 - 1:50pm

PARIS October 29, 2020 The European Patent Office (EPO) Technical Boards of Appeal has today ruled in Sanofi and Regenerons favor, invalidating certain claims of Amgens European patent (EP 2 215 124) directed to PCSK9 (proprotein convertase subtilisin/kexin type 9) antibodies relevant to Praluent (alirocumab).

Key Points: 
  • PARIS October 29, 2020 The European Patent Office (EPO) Technical Boards of Appeal has today ruled in Sanofi and Regenerons favor, invalidating certain claims of Amgens European patent (EP 2 215 124) directed to PCSK9 (proprotein convertase subtilisin/kexin type 9) antibodies relevant to Praluent (alirocumab).
  • Praluent will continue to be available in European countries where it is approved for use and for sale.
  • Praluent was developed by Sanofi and Regeneron under a global collaboration agreement.
  • With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Ecogensus Receives Notice of Allowance from European Patent Office for Waste-to-Fuel Process

Countries, Government, Law, European Patent Organisation, Waste management, Waste, Landfill, Municipal solid waste, European Patent Office, Patent, European Patent Convention
Monday, October 26, 2020 - 8:29pm

HARTFORD, Conn., Oct. 26, 2020 /PRNewswire/ --Ecogensus, LLC ("Ecogensus" or the "Company"), a leading technology company in the resource recovery and waste management industry, today announced the European Patent Office's issuance of a notice that it intends to grant a patent for the Company's process of converting solid wastes into fuel (European Patent Application No.

Key Points: 
  • HARTFORD, Conn., Oct. 26, 2020 /PRNewswire/ --Ecogensus, LLC ("Ecogensus" or the "Company"), a leading technology company in the resource recovery and waste management industry, today announced the European Patent Office's issuance of a notice that it intends to grant a patent for the Company's process of converting solid wastes into fuel (European Patent Application No.
  • The new European patent covers the foundational process for conversion of solid wastes into a fuel, a process which enables diversion from waste from landfills and displacement of coal with Ecogensus' waste-derived fuel.
  • "We are very pleased with this new addition to our patent portfolio in the waste-to-value space," commented Bjrnulf stvik, Ecogensus' CEO and CTO.
  • This new notice of allowance from the EPO broadens the growing global patent protection of our waste processing solutions."